| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Gary Sender is Director at SDGR and has filed Form 4s across 2 companies. Gary Sender's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $698K at current prices.
The biggest single holding is SDGR (~$690K) as Director. The SDGR filings lean toward selling, a net 28,775 shares.
Gary Sender has 22 Form 4 filings on record from February 2020 to October 2026, across 4 companies: Director at iBio (IBIO), 2020–2026; Director at Apnimed (APMD), 2026; Director at Schrödinger (SDGR), 2020–2026, and 1 more.
The 34 reported transactions were 23 option or other derivative awards, 4 stock awards, 3 dispositions back to the company and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $25K and 1 sale worth about $1.9M.
The only open-market purchase was 9,191 shares of IBIO at an average $2.72 on January 10, 2025, about $25K. Twelve months later IBIO was up 6%.
The only open-market sale was 28,775 shares of SDGR at an average $66.55 on March 8, 2021, about $1.9M.